Most Read Articles
23 Nov 2017
In patients with rheumatoid arthritis (RA) who are also positive for anticitrullinated protein antibodies (ACPA), tocilizumab (TCZ) treatment for 2 years increases femoral neck bone mineral density (BMD) and decreases concentrations of bone resorption markers, a recent study has found.
12 Nov 2017
Tocilizumab may improve skin score and forced vital capacity stabilization in patients with systemic sclerosis, while potentially increasing the risk of serious infections, according to the open-label data of the faSScinate* trial.
Audrey Abella, 21 Nov 2017
The infliximab (IFX) biosimilar SB2, whether administered long-term or switched from IFX, had comparable efficacy and safety as IFX for rheumatoid arthritis (RA), a study has found.
30 Nov 2017
There are significant associations between comorbidities and hand osteoarthritis (OA) disease burden, a recent study has found.

Chronic Pain Control: What's Adequate and Appropriate?

18 Aug 2016
Reducing back pain starts with emptying your bag
During the combined meeting of the 46th Malaysian Orthopaedic Association Annual General Meeting/Annual Scientific Meeting and the 10th ASEAN Arthroplasty Association Meeting, Dr Joseph Pergolizzi spoke on the importance of chronic pain control and appropriate strategies to achieve this. Highlights of his presentation are summarized below.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
23 Nov 2017
In patients with rheumatoid arthritis (RA) who are also positive for anticitrullinated protein antibodies (ACPA), tocilizumab (TCZ) treatment for 2 years increases femoral neck bone mineral density (BMD) and decreases concentrations of bone resorption markers, a recent study has found.
12 Nov 2017
Tocilizumab may improve skin score and forced vital capacity stabilization in patients with systemic sclerosis, while potentially increasing the risk of serious infections, according to the open-label data of the faSScinate* trial.
Audrey Abella, 21 Nov 2017
The infliximab (IFX) biosimilar SB2, whether administered long-term or switched from IFX, had comparable efficacy and safety as IFX for rheumatoid arthritis (RA), a study has found.
30 Nov 2017
There are significant associations between comorbidities and hand osteoarthritis (OA) disease burden, a recent study has found.